Limitless Venture Group Inc (OTCMKTS:LVGI) shares were up 14.29% on Wednesday after the company announced that it will start production of its flagship product, SLAM INFUSINATION RTD. The company has a market cap of $4.14 million at 2.48 billion shares outstanding. Share prices have been trading in a 52-week range of $0.00 to $0.00.
Limitless Venture Group Inc is a development-stage company that is engaged in the production, distribution and marketing of product lines in the nutraceutical sector. Formerly known as Enerbrite Technologies Group Inc, its Limitless Body line offers body care products designed for the sport of bodybuilding. SLAM INFUSINATION products are Haymaker, CoCo-Puff, Red Headed Slut, Twist and Kamikaze, which are ready-to-drink alcoholic shots.
In its latest press release, Limitless Venture Group announced that it has produced the first initial production run of SLAM INFUSINATION RTD products. The initial order was for 12,000 of the products and the first completed production run was of Cojak, which is a blend of alcohol with cola and whiskey flavors. The second production run for Haymaker, which is a blend of alcohol with lemon and tea flavors, was delayed due to Hurricane Hermine.
“This is a day for us all to be proud of. We have production of our flagship product SLAM INFUSINATION RTD DRINKS,” said Limitless Venture Group CEO Joseph Francella. “We have also signed an agreement with Bomb Spirits, LLC located in Carefree, Arizona to warehouse this initial production run of SLAM products. Ufoods USA brokered this deal and will be working closely with Bomb Spirits, to bring SLAM to market.”
Bomb Spirits is known for its C4 gelatin shot that is popular in the greater Phoenix area. With that, Arizona should prove as the main test market for SLAM products, with a release party being coordinated near the Arizona State University. Francella concluded that this is the beginning of a long and prosperous relationship between the two companies.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.